AI-empowered Nudge to Improve Colonoscopy Uptake (AINC)
AI-empowered Nudge to Improve Colonoscopy Uptake (AINC): A Pragmatic Cluster-Randomized Trial
Colorectal cancer (CRC) ranks third in both incidence and mortality among all malignant tumors in China. Studies have shown that early screening can significantly reduce its incidence and mortality. Colonoscopy is the gold standard for CRC screening; however, compliance with colonoscopy among high-risk groups in China is very low. Artificial intelligence (AI)-assisted tools can provide real-time, personalized health education, and nudge strategies can help translate intent into action. This trial aims to evaluate the effectiveness of AI-empowered nudge for improving colonoscopy uptake among high-risk individuals aged 45 to 74 in China. It's a two-arm, pragmatic cluster randomized controlled trial. The main question it aims to answer is whether the AI-enabled personalized health education and nudge strategies improve colonoscopy adherence.
Participants will:
- Be recruited and allocated into one of two groups according to the assigned clusters. Participants in one group will be invited to receive usual care. In addition to usual care, participants in the other group will receive AI-empowered nudge, featuring an AI chatbot providing real-time personalized responses and a nudge environment with default screening option.
- Have their colonoscopy status checked at the end of trial.
調査の概要
詳細な説明
We will conduct a two-arm, parallel-group, cluster-randomized controlled trial to evaluate the effectiveness of an AI-empowered nudge model in improving colonoscopy uptake (AINC) among high-risk individuals aged 45 to 74. The AI-empowered nudge model combines default screening nudging with an AI chatbot on colorectal cancer screening. We will also evaluate the feasibility of this AINC model, and identify the facilitators and barriers to its real-world adoption.
The colonoscopy uptake rate is approximately 15% in China, and the proposed intervention is expected to increase this rate by 10%. Sample size calculation, based on detecting an increase in colonoscopy uptake from 15% to 25% with 90% power (α=0.05, two-sided), an ICC of 0.05, and 30 clusters per arm, indicates a need for 24 participants per cluster. There are 720 per arm, and 1440 in total. Allowing for 15% attrition, the final sample size is determined to be 1680 from 70 clusters. As a pragmatic trial in real world, the number of participants each cluster depends on the population size of the respective villages or communities. All eligible participants in the participating villages or communities will be included in the study.
Participant recruitment will be conducted across 70 villages/communities in three representative counties/cities in China, covering urban, suburban, and rural areas. Cluster randomisation will be performed at the level of villages or communities using a stratified block design to ensure balanced allocation across the two trial arms. Stratification factors include geographic access to colonoscopy hospital and the size of individuals aged 45 to 74 for each cluster. Clusters with comparable levels of these factors will be grouped into blocks within each city and then randomly assigned within each block to the AINC or control group. The random allocation sequence will be generated by an independent statistician using a computer-based random number generator in R software and implemented via a secure centralised system.
The study procedure involves first identifying high-risk individuals for CRC through an initial risk assessment questionnaire and a fecal immunochemical test (FIT). Those who meet the criteria will then receive the intervention corresponding to their village's assigned study arm. Participants in the intervention group will receive an AI-powered nudge for colonoscopy (AINC), featuring an AI chatbot providing real-time personalized responses and a nudge environment with default screening option, followed by message reminders once per two weeks. The control group will receive usual care. Colonoscopy uptake will be collected via the hospital information system at the 3-month follow-up.
The primary analysis will follow the intention-to-treat (ITT) principle, while the per-protocol (PP) analysis will serve as the secondary analysis. In the ITT analysis, all subjects randomized to each group will be included. Between-group comparisons for continuous and categorical variables will utilize t-tests and chi-square tests. The primary outcome (colonoscopy uptake) will be analyzed using Generalized Estimating Equations (GEE), adjusting for cluster effects and relevant covariates to obtain robust estimates. Covariates include region, age, sex, smoking history, Body Mass Index, history of bowel-related symptoms or diseases, and family history. The timing of colonoscopy uptake will be analyzed using Kaplan-Meier survival curves and log-rank tests, and the intervention effects on the time-to-event will be quantified with a Cox proportional hazards model. Subgroup analyses will be conducted to elucidate the effect heterogeneity across populations stratified by pre-specified characteristics, including region, age, sex, smoking history, Body Mass Index, history of bowel-related symptoms or diseases, and family history.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Zhiyuan Hou, PhD
- 電話番号:86+21 54231112
- メール:zyhou@fudan.edu.cn
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Aged 45-74 years;
- Test positive on the Colorectal Cancer Risk Assessment Scale and the immunochemical fecal occult blood test;
- In good general health, mentally competent;
- Provide informed consent.
Exclusion Criteria:
- History of colorectal resection;
- Previous diagnosis of cancer or currently undergoing any cancer-related treatment;
- Underwent a colonoscopy or sigmoidoscopy within the past 5 years;
- Contraindications to colonoscopy (e.g. severe cardiac, cerebral, lung diseases, or renal dysfunction).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:AI-empowered nudge group
This arm implements a multi-component AI-empowered nudge strategy: Default Appointment: On-site pre-scheduling of colonoscopies for high-risk individuals, providing an "opt-out" mechanism. AI Chatbot: Guided on-site use (≥3 mins) of a dedicated chatbot offering personalized responses on CRC questions to facilitate self-learning. LLM-produced SMS Reminders: For non-adherent participants, ChatGPT-5 generates risk-tailored SMS reminders sent bi-weekly to participants and their families (5 times). |
A digital health education and behavioral nudge intervention.
It utilizes an intelligent chatbot to provide real-time, personalized information about colonoscopy and implements a default screening mechanism to facilitate the translation from screening intention to behavior.
|
|
アクティブコンパレータ:Control Group
Usual care: Based on the results of the risk assessment questionnaire and FIT test, village doctors will notify the screening results to colorectal cancer high-risk individuals, and instructs recipients to go to the designated hospital for a colonoscopy.
Colonoscopy appointments will be scheduled only for residents who are willing to undergo a colonoscopy.
|
Usual notification of screening results and opt-in appointment for colonoscopy.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Uptake of colonoscopy
時間枠:Three months after recruitment
|
Defined as whether the participant completes the colonoscopy.
Data will be collected through the Hospital Information System (HIS) using participants' identification.
|
Three months after recruitment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to completion of colonoscopy
時間枠:Three months after recruitment
|
The interval from intervention initiation to the colonoscopy procedure.
Data will be collected from information systems of hospitals.
|
Three months after recruitment
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
User engagement level with intervention
時間枠:Three months after recruitment
|
Assessed by the issuing number of appointment card and chatbot usage metrics, including usage frequency, interaction duration, and the number of questions asked.
Data will be obtained through backend system logs.
|
Three months after recruitment
|
|
Usability of AI-empowered Nudge Intervention
時間枠:Three months after recruitment
|
The usability of the intervention will be evaluated using a series of questions on its feasibility, acceptability, and sustainability, as well as the facilitators and barriers of its implementation.
Data will be collected via semi-structured interviews.
|
Three months after recruitment
|
|
Intervention Cost
時間枠:Three months after recruitment
|
The costs associated with both study arms obtained through work logs, including expenses for doctor manpower, chatbot development, and usage.
Unit of Measure: Chinese Yuan (CNY).
|
Three months after recruitment
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Zhiyuan Hou, PhD、Fudan University
出版物と役立つリンク
一般刊行物
- Zhang Q, Wong AKC, Bayuo J. The Role of Chatbots in Enhancing Health Care for Older Adults: A Scoping Review. J Am Med Dir Assoc. 2024 Sep;25(9):105108. doi: 10.1016/j.jamda.2024.105108. Epub 2024 Jun 22.
- Maida M, Mori Y, Fuccio L, Sferrazza S, Vitello A, Facciorusso A, Hassan C. Exploring ChatGPT effectiveness in addressing direct patient queries on colorectal cancer screening. Endosc Int Open. 2025 May 12;13:a25689416. doi: 10.1055/a-2568-9416. eCollection 2025.
- Heald B, Keel E, Marquard J, Burke CA, Kalady MF, Church JM, Liska D, Mankaney G, Hurley K, Eng C. Using chatbots to screen for heritable cancer syndromes in patients undergoing routine colonoscopy. J Med Genet. 2021 Dec;58(12):807-814. doi: 10.1136/jmedgenet-2020-107294. Epub 2020 Nov 9.
- Chen D, Avison K, Alnassar S, Huang RS, Raman S. Medical accuracy of artificial intelligence chatbots in oncology: a scoping review. Oncologist. 2025 Apr 4;30(4):oyaf038. doi: 10.1093/oncolo/oyaf038.
- Dougherty MK, Brenner AT, Crockett SD, Gupta S, Wheeler SB, Coker-Schwimmer M, Cubillos L, Malo T, Reuland DS. Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018 Dec 1;178(12):1645-1658. doi: 10.1001/jamainternmed.2018.4637.
- Yu Z, Li B, Zhao S, Du J, Zhang Y, Liu X, Guo Q, Zhou H, He M. Uptake and detection rate of colorectal cancer screening with colonoscopy in China: A population-based, prospective cohort study. Int J Nurs Stud. 2024 May;153:104728. doi: 10.1016/j.ijnurstu.2024.104728. Epub 2024 Feb 20.
- Chen H, Li N, Ren J, Feng X, Lyu Z, Wei L, Li X, Guo L, Zheng Z, Zou S, Zhang Y, Li J, Zhang K, Chen W, Dai M, He J; group of Cancer Screening Program in Urban China (CanSPUC). Participation and yield of a population-based colorectal cancer screening programme in China. Gut. 2019 Aug;68(8):1450-1457. doi: 10.1136/gutjnl-2018-317124. Epub 2018 Oct 30.
- Chen Y, Zhang Y, Yan Y, Han J, Zhang L, Cheng X, Lu B, Li N, Luo C, Zhou Y, Song K, Iwasaki M, Dai M, Wu D, Chen H. Global colorectal cancer screening programs and coverage rate estimation: an evidence synthesis. J Transl Med. 2025 Jul 22;23(1):811. doi: 10.1186/s12967-025-06887-4.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- Fudan-AINC
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。